Skip to content

Nuvalent, Inc. NUVL Common Stock

Common Stock at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
1.7B+22.2%
Summit Therapeutics logo
Summit TherapeuticsSMMT
1B0.0%
Exelixis logo
ExelixisEXEL
400M0.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$19K+5.6%
Incyte logo
IncyteINCY
400M0.0%
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Nuvalent, Inc.’s 10-Q, filed September 8, 2021, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s common stock?
Nuvalent, Inc. (NUVL) reported common stock of 228.6M in Q2 2021.